RecruitingPhase 2NCT05709314
A Study of AMDX-2011P in Participants With CAA
Studying Hereditary cerebral amyloid angiopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amydis Inc.
- Intervention
- AMDX-2011P(drug)
- Enrollment
- 25 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Associated Retina Consultants, Phoenix, Arizona, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05709314 on ClinicalTrials.govOther trials for Hereditary cerebral amyloid angiopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06714097Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project)Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGPHASE2NCT06393712A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid AngiopathyAlnylam Pharmaceuticals
- RECRUITINGNCT04204642SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- ACTIVE NOT RECRUITINGNCT06128824High Frequency Imaging in Cerebral Amyloid AngiopathyMartin Dichgans